الفهرس 
INFLAMMATORY BOWEL DISEASESOnly 14 pages are availabe for public view
 |  | from | 209 |  |  |
| | | from | 209 | | |
Abstract
Abstract:
IBD is a chronic and recurring inflammatory condition of the gastrointestinal system that has an unknown cause and is marked by periods of relapse and remission. It causes long-term impairment of the structure and function of the gastrointestinal tract. The gold standard to establish diagnosis and assess disease activity remains endoscopy and histopathology. In order to promptly diagnose IBD and evaluate the severity of the disease, it is necessary to utilize non-invasive biomarkers, as the majority of patients are unwilling to undergo endoscopic testing. IBD patients had elevated levels of serum galectin-3 in comparison to healthy individuals. Galectins 3 in serum have the capacity to function as biomarkers for the identification of IBD and the evaluation of disease activity. The present research examines the significance of galactin 3 as an ideal diagnostic biomarker for determining the level of disease activity in individuals with ulcerative colitis (UC). We collected serum and fecal samples from 40 individuals who were diagnosed with active ulcerative colitis (UC), and also from 40 healthy individuals who served as controls. The serum levels of galactin 3 were notably significantly greater in patients with active UC compared to the control group (p<0.001). The threshold level of serum Galactin 3 for identifying disease activity was found to be greater than 94.8 ng/mL, with a sensitivity of 100% and a specificity of 97.5%. Nevertheless. Nevertheless, the amalgamation of blood galactin 3, Utilizing both C-reactive protein (CRP) and fecal calprotectin (FC) together demonstrated higher precision in predicting disease activity compared to utilizing each biomarker individually, achieving a sensitivity and specificity of 100%.